medigraphic.com
Instituto Nacional de Salud Pública

2016, Number 2

<< Back Next >>

salud publica mex 2016; 58 (2)

Eradication of cervical cancer in Latin America

Bosch FX

Language: English
References: 19
Page: 97-100
PDF size: 193.82 Kb.


ABSTRACT

Cervical cancer remains within the three most common cancer in women worldwide and is still the commonest female cancer in 41 of 184 countries. Within Latin America, cervical ranks as the most common cancer among women in Bolivia and Peru and the second most frequent in Brazil, Colombia, Ecuador, Mexico, Paraguay, The Guyanas, Surinam and Venezuela.


REFERENCES

  1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet], [accessed March, 2015]. Available at: http://globocan.iarc.fr.

  2. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. 2012. Global Burden of Human Papillomavirus and Related Diseases’. Vaccine 2012, 30 (suppl 5):F12-F23. doi:10.1016/j.vaccine. 2012.07.055.

  3. Institute of Medicine/Forum on Emerging Infections. Considerations for viral disease eradication lessons learned and future strategies: workshop summary. In: Knobler S, Lederberg J, Pray LA. Washington, DC: National Academy Press, 2002 [accessed March, 2015]. Available at: http://search. ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk &AN=86910.

  4. Arbyn MA, Haelens A, Desomer A, Verdoodt F, Thiry N, Francart J, et al. Cervical cancer screening program and Human Papillomavirus (HPV) testing, Part II: Update on HPV primary screening. Health Technology Assessment (HTA) KCE Reports 238Cs. D/2015/10.273/16. Brussels: Belgian Health Care Knowledge Centre (KCE), 2015.

  5. Cuzick J, Szarewski A, Mesher D, Cadman L, Austin J, Perryman K, et al. Long-term follow-up of cervical abnormalities among women screened by hpv testing and cytology-results from the Hammersmith Study. Int J Cancer 2008;122(10):2294-2300. doi:10.1002/ijc.23339.

  6. Ronco G, Dillner J, Miriam-Elfström K, Tunesi S, Snijders PJF, Arbyn M, et al. 2014. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383 (9916):524-532. doi:10.1016/S0140-6736(13)62218-7.

  7. U.S. Food and Drug Administration. WebContent. 2014. ‘News Release - FDA Approves First Human Papillomavirus Test for Primary Cervical Cancer Screening, April 24. FDA, 2014. [accessed March, 2015]. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm394773.htm.

  8. Lehtinen M, Dillner J. Clinical Trials of Human Papillomavirus Vaccines and beyond. Nat Rev Clin Oncol 2013;10(7):400-410. doi:10.1038/nrclinonc. 2013.84.

  9. Michela S, Carrillo-Santisteve P, Lopalco PL. Safety of Human Papillomavirus Vaccines: A Review. Expert Opinion on Drug Safety 2015;14(5):697- 712. doi:10.1517/14740338.2015.1013532.

  10. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of Human Papillomavirus 16/18 L1 Virus like particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007;298(7):743-753. doi:10.1001/jama.298.7.743.

  11. Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PloS One 2013;8(7):e68329. doi:10.1371/journal.pone.0068329.

  12. Garland SM. The Australian Experience with the Human Papillomavirus Vaccine. Clinical Therapeutics 2014;36(1):17-23. doi:10.1016/j.clinthera. 2013.12.005.

  13. Hariri S, Bennett NM, Niccolai LM, Schafer S, Park IU, Bloch KC, et al. Reduction in HPV 16/18-Associated High Grade Cervical Lesions Following HPV Vaccine Introduction in the United States - 2008-2012. Vaccine 2015;33(13):1608-1613. doi:10.1016/j.vaccine.2015.01.084.

  14. Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women. J Natl Cancer Inst 2014;106(3):djt460. doi:10.1093/jnci/djt460.

  15. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-Valent HPV Vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015;372(8):711-723. doi:10.1056/NEJMoa1405044.

  16. Drolet M, Bénard E, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population- level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infectious Diseases 2015;15(5):565-580. doi:10.1016/S1473-3099(14)71073-4.

  17. Tabrizi SN, Brotherton JML, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. 2014. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infectious Diseases 2014;14(10):958-966. doi:10.1016/ S1473-3099(14)70841-2.

  18. Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, et al. End-of-Study Safety, Immunogenicity, and Efficacy of Quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011;105(1):28-37. doi:10.1038/bjc.2011.185.

  19. Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce L, Salmerón J, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-Adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the Phase 3, Double-Blind, Randomised Controlled VIVIANE Study. Lancet 2014;384(9961):2213-2227. doi:10.1016/ S0140-6736(14)60920-X.




2020     |     www.medigraphic.com